<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:240413648;
mso-list-template-ids:-1896959992;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1255095556;
mso-list-template-ids:274220288;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1742436980;
mso-list-template-ids:255651702;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1781562368;
mso-list-template-ids:-1353646560;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="color:#1F497D"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><u><span style="font-size:12.0pt;font-family:Palatino;color:#0070C0">Note Regarding NSF Biosketch Requirements:<o:p></o:p></span></u></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Effective October 5, 2020, the National Science Foundation (NSF) will begin enforcing the Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 20-1) requirement to use NSF-approved
formats for the preparation of the Biographical Sketch and Current and Pending Support proposal documents. The NSF-approved formats are SciENcv: Science Experts Network Curriculum Vitae and an NSF fillable PDF.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NSF <span style="color:#1F497D">
<a href="https://urldefense.com/v3/__https://www.nsf.gov/bfa/dias/policy/biosketch.jsp__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2a4a7fRQ$">Biographical Sketch</a>
</span>and<span style="color:#1F497D"> <a href="https://urldefense.com/v3/__https://www.nsf.gov/bfa/dias/policy/cps.jsp__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2XNgrXZ8$">
Current and Pending Support</a> </span>websites include links to the NSF-fillable PDF formats, updated FAQs, and instructions<span style="color:#1F497D">.<o:p></o:p></span></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-289.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2p2c5_iU$" target="_blank">NIAID Research Education Program (R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The overarching goal of this NIAID R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral
and clinical research needs of NIAID <a href="https://urldefense.com/v3/__https://www.niaid.nih.gov/about/help-our-mission__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2lMabLJs$">
mission</a> areas.<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><i><span style="font-size:12.0pt;font-family:Palatino">Courses for Skills Development:
</span></i></b><span style="font-size:12.0pt;font-family:Palatino">It is expected that the course(s) for skills development provide innovative, state-of-the-art, evidence-based education that relates to the mission of NIAID, and is derived from biomedical,
behavioral or clinical research findings. For example, advanced courses in a specific discipline or research area, clinical procedures for research, specialized research techniques, or research methodology. The courses may include elements that promote research
skills and career skills of the participants. The format of the courses may involve a traditional in-person approach, online activities, a hybrid of both approaches, or other methods.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><i><span style="font-size:12.0pt;font-family:Palatino">Research Experiences:
</span></i></b><span style="font-size:12.0pt;font-family:Palatino">It is expected that the research experiences supported by this FOA are relevant to the trainees area of science, yet sufficiently different such that it expands or extends their skills. The
expanded experience has to meet the needs and career level of participants. Research experiences must also be designed to address some area of NIAID extramurally supported research. For example, for graduate and health professional students: to provide research
experiences and related training not available through formal NIH training mechanisms; to provide hands-on authentic research experiences that reflect ownership of a project and provide opportunity for meaningful contribution to the research in question, and
stimulate their interest to consider further education and training for future research related to the NIAID mission; for postdoctorates and junior faculty: to extend their skills, experiences, and knowledge base and prepare them for a NIAID-related career
research.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><i><span style="font-size:12.0pt;font-family:Palatino">Mentoring Activities:
</span></i></b><span style="font-size:12.0pt;font-family:Palatino">Within the context of a mentoring network activities may include, but are not limited to, dedicated efforts at providing technical expertise, advice, insight, and professional career skills
that advance the broad career goals of graduate students, postdoctorates and/or early-career faculty; facilitating scholarly writing and grantsmanship; promoting successful transitions from one career stage to another; providing leadership development; helping
to identify potential collaborators; helping to establish interdisciplinary or translational collaborations in order to foster a career trajectory towards independent NIAID-related research.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 7, 2020; December 7, 2021; and December 7, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for December 2020 due date: November 23.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20609/nsf20609.htm__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2RlyJNkA$">NSF’s Collaborative Research in Computational Neuroscience (CRNS): Innovative Approaches to Science and Engineering Research
on Brain Function</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Computational neuroscience provides a theoretical foundation and a rich set of technical approaches for understanding complex neurobiological systems, building on the theory, methods,
and findings of computer science, neuroscience, and numerous other disciplines. Through the CRCNS program, the U.S. National Science Foundation (NSF), National Institutes of Health (NIH), and Department of Energy (DOE); the German Federal Ministry of Education
and Research (Bundesministerium für Bildung und Forschung, BMBF); the French National Research Agency (Agence Nationale de la Recherche, ANR); the United States-Israel Binational Science Foundation (BSF); Japan’s National Institute of Information and Communications
Technology (NICT); and Spain’s State Research Agency (Agencia Estatal de Investigación, AEI) and National Institute of Health Carlos III (Instituto de Salud Carlos III, ISCIII) support collaborative activities that will advance the understanding of nervous
system structure and function, mechanisms underlying nervous system disorders, and computational strategies used by the nervous system. Two classes of proposals will be considered in response to this solicitation:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research Proposals</span></b><span style="font-size:12.0pt;font-family:Palatino"> describing collaborative research projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Data Sharing Proposals</span></b><span style="font-size:12.0pt;font-family:Palatino"> to enable sharing of data and other resources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 10, 2020; November 23, 2021; November 22, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for December 2020 due date: November 30.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-299.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2z49cW3U$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-300.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2PNw0Thg$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these funding opportunity announcements is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying
mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve
drug safety and efficacy for maternal and pediatric precision therapeutics.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 10, 2020; April 9, 2021; August 10, 2021; December 10, 2021; April 11, 2022; August 10, 2022; and December 9, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for December 2020 due date: November 30.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-556.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2GeB2T_8$" target="_blank">BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across
vertebrate species (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies,
production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources
for cell type-specific access and manipulation reagents for several vertebrate species, including in human
<i>ex vivo</i> tissues or cells. Demonstration projects are sought that would develop reagents that: (1) enable access to molecularly defined neural cell types in a complex brain region or significant brain network of a vertebrate; (2) are easily produced,
disseminated, utilized, and stored; and (3) are catalogued for users in a brain atlas. In addition to the above required features, reagents are also sought that exhibit the following qualities: (4) are applicable to both genetically tractable and less tractable
vertebrate organisms; (5) exhibit high specificity and efficiency of targeting; (6) show low toxic or perturbative effects; (7) provide flexibility to deliver various reporter, sensor, and effector payloads and are compatible with other methods of access to
brain cell types; and (8) are potentially usable in human <i>ex vivo</i> brain tissue or cells. The pilot projects should be scalable in the future. The long-term goal of a potentially scaled-up effort is to achieve near comprehensive, molecular access for
monitoring and manipulation reagents in each defined cell type of vertebrate brains relevant to neuroscience research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 11, 2021 and October 19, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for February 2021 due date: February 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-051.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2-NuL42Q$" target="_blank">Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in
Rural Populations (R01 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable
risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical
activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities.
This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and
adaptation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 15, 2021 and January 18, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for March 2021 due date: March 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-298.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso2FA5u5rc$" target="_blank">Development of the Fetal Immune System (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development
of the fetal immune system.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 7, 2021; December 7, 2021; April 7, 2022; December 7, 2022; April 7, 2023; and December 7, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for April 2021 due date: March 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-296.html__;!!PhOWcWs!i8mDggbY6jt9Zd5B2FpJwehguLXpj23-h-LSkEAcXxp-lbtjwLGafyvNm1LB3k64ut9rBbacHso28AM9oP0$" target="_blank">Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities
that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><b><i><span style="font-size:12.0pt;font-family:Palatino">Curriculum or Methods Development</span></i></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the broader community to enhance training of the biomedical research
workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 18, 2021; June 20, 2022; and June 19, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 2021 due date: June 7.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><span style="font-size:12.0pt"><o:p></o:p></span></p>
</div>
</body>
</html>